(Q45935217)

18 December 2017

review article

1 reference

title

Long-term antithrombotic treatment for atrial fibrillation. (English)

1 reference

18 December 2017

1 reference

K Nademanee

1

1 reference

18 December 2017

E M Kosar

series ordinal

2

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 October 1998

1 reference

18 December 2017

American Journal of Cardiology

published in

1 reference

18 December 2017

volume

82

1 reference

18 December 2017

issue

8A

1 reference

18 December 2017

page(s)

37N-42N

1 reference

18 December 2017

Epidemiologic features of chronic atrial fibrillation: the Framingham study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Antithrombotic therapy in atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Canadian atrial fibrillation anticoaguiation (CAFA) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Stroke Prevention in Atrial Fibrillation Study. Final results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Atrial fibrillation and stroke: new ideas, persisting dilemmas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Increased intracardiovascular clotting in patients with chronic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

Antithrombotic therapy in atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900738-3

10.1016/S0002-9149(98)00738-3

7 January 2021

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017